that causes blindness is tested
Physicians at the School of Medicine are testing a new light-sensitive drug used to treat the most severe form of macular degeneration, the leading cause of blindness in people over age 50.
The drug, verteporfin, is expected to receive approval by the U.S. Food and Drug Administration in the next few weeks under the name Visudyne. The Department of Ophthalmology and Visual Science has been holding clinical trials of the drug for four months at the Yale Eye Center.
"Verteporfin is a photosensitizing agent that is injected into the patient's arm," explains Dr. Daniel Berinstein, assistant professor of ophthalmology. "The medication is then activated by light from a laser for about 90 seconds. The laser is weak enough so that it does not damage the retina, but strong enough to activate the medication and selectively treat the abnormal blood vessels associated with the degeneration."
Once activated, the verteporfin works by closing the abnormal blood vessels and, it is hoped, improving or stabilizing the patient's vision.
The clinic administered the treatment to about 12 patients and a three-month follow up is in progress to determine the effectiveness of the procedure. The drug's developers, CIBA Vision and QLT PhotoTherapeutics, found in their own study that the treatment led to improvement for some, but not all, patients. The latter included patients with longstanding vision loss or those whose eye or eyes had already been significantly damaged by age-related macular degeneration (AMD). AMD affects the central field of vision essential for activities such as reading and driving. Peripheral, or side vision, is retained.
There are two types of AMD. The "dry" form is found in 85% of patients with AMD and is characterized by deposits of yellow material in the retina.
The new treatment is designed for the more severe, but less common, "wet" AMD, which, although it affects only 15% of patients with AMD, accounts for 90% of severe vision loss associated with the condition.
The wet form of AMD is caused by the growth of abnormal blood vessels across the macula, or the central part of the retina. These abnormal vessels leak fluid and blood into the tissue at the back of the eye, causing a blister to form in the retina. This leads to scar tissue and a large blind spot.
AMD tends to occur in one eye at a time, but 50% of patients with wet AMD in one eye will develop the condition in their second eye within five years. The progression of the disease varies from a few months to three years. If untreated, the majority of eyes affected with wet AMD will become functionally blind within three years.
One of the first noticeable symptoms of wet AMD is a distortion of straight lines.
Berinstein said the only other approved treatment currently available for 10% to 20% of cases of wet AMD is laser photocoagulation, where laser light is used to destroy the abnormal leaky blood vessels. But because this treatment is non-selective, the overlying and surrounding retina is also destroyed, causing permanent central vision loss.
-- By Jacqueline Weaver
T H I S
Bulletin Home
W E E K ' SS T O R I E S
Mathematician Ronald Coifman wins National Medal of Science
DeVita helping to shape nation's future strategy in the war on cancer
Concert by Yale Band will recall Glenn Miller era
Hustler publisher hails freedom of speech
Journalist Jonathan Rauch decries special interest groups
Influential architecture journal celebrates 50th year
Research shows patients with mental illnesses may get inadequate care after a heart attack
Discovery holds promise for reversing brain, spinal injury
Interdisciplinary studies to be focus of conference
Event will explore challenges of city management
Colgate-Palmolive official to discuss global strategy
YALE CANCER CENTER NEWS
Technology center at Stetson Library will help to bridge 'digital divide'
Africana specialist Woodson is new curator of Yale collection
Researchers find new stars in Milky Way's 'halo'
New drug to treat ailment that causes blindness is tested
Park ranger chosen as Yale Younger Poet
Alvin M. Liberman, specialist in psychology of speech, dies
Yale students will 'Stand Up and Dance' to make a difference
Special program celebrates modernist artists of WWI 'blast'
Comedy and characterizations combine in 'To the Top Top Top!' one-woman show
New SOM program examines changing economic landscape
White House recalls the legacy of C. Vann Woodward
Concerts raise funds to aid victims of Taiwan earthquake
Yale Scoreboard
. . . In the News . . .|Visiting on Campus|
Calendar of Events|Bulletin Board
Classified Ads|Search Archives|Production Schedule|Bulletin Staff
Public Affairs Home|News Releases|
E-Mail Us|Yale Home Page